<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019105</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 1140-001</org_study_id>
    <nct_id>NCT05019105</nct_id>
  </id_info>
  <brief_title>Phase 1 ALKS 1140 in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Escalating Doses of ALKS 1140 With a Pilot Evaluation of Food Effect in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of ALKS 1140 in healthy adult subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Change in C-SSRS measured in Multiple-Ascending Dose subjects only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead safety ECG results</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>ECG parameters (Heart Rate, RR, PR, QRS, QT, QTcF, T wave) will be analysed using descriptive summary statistics (mean, standard deviation, median, minimum, and maximum for continuous variables) and as a change from baseline by dose level and treatment group. For the QT interval assessment, clinically abnormal ECG results for QTcF will be tabulated by protocol-specified millisecond range categories by dose and treatment group. Potentially clinically significant findings will be summarized by dose and treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) for ALKS 1140</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of ALKS 1140</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until first quantifiable concentration (tlag)</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase (Vz/F)</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance following oral administration (CL/F)</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QTcF (Fridericia method) interval in response to treatment (Holter monitoring)</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (RA)</measure>
    <time_frame>Measured at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 1140</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 8 single ascending doses of ALKS 1140 and 4 multiple ascending doses administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 1140</intervention_name>
    <description>Active oral dose of ALKS 1140</description>
    <arm_group_label>ALKS 1140</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) â‰¥18 and &lt;30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illness or disease including significant cardiac,&#xD;
             gastrointestinal (stomach)&#xD;
&#xD;
          -  Subjects who have known allergic reactions to food or medications&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Any clinically significant lifetime history of suicidal behavior or ideation&#xD;
             (thoughts)&#xD;
&#xD;
          -  Subject had lymphoma, leukemia, or any malignancy within the past 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>888-235-8008 (US Only)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>1-571-599-2702 (Global)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alkermes Clinical Investigative Site</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

